BioNTech (BNTX) to Release Earnings on Monday

BioNTech (NASDAQ:BNTX) is expected to be announcing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of $0.57 per share and revenue of $1.2054 billion for the quarter. BioNTech has set its FY 2025 guidance at EPS.Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 3, 2025 at 8:00 AM ET.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $306.46 million during the quarter, compared to the consensus estimate of $161.26 million. During the same quarter in the prior year, the firm posted ($3.36) earnings per share. The company’s revenue was up 102.6% on a year-over-year basis. On average, analysts expect BioNTech to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

BioNTech Trading Up 0.9%

Shares of BNTX opened at $105.66 on Monday. The business’s 50-day moving average price is $103.20 and its 200-day moving average price is $104.66. BioNTech has a twelve month low of $81.20 and a twelve month high of $129.27. The stock has a market cap of $23.79 billion, a PE ratio of -66.04 and a beta of 1.45. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on BNTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Tuesday, October 14th. Bank of America decreased their price objective on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, October 22nd. JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a research report on Thursday. Morgan Stanley decreased their price objective on shares of BioNTech from $133.00 to $131.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Finally, Wells Fargo & Company set a $150.00 price objective on shares of BioNTech and gave the stock an “overweight” rating in a research report on Tuesday, August 5th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $133.96.

Institutional Trading of BioNTech

Several hedge funds and other institutional investors have recently bought and sold shares of BNTX. Tower Research Capital LLC TRC boosted its stake in BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after buying an additional 305 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in shares of BioNTech during the first quarter valued at approximately $167,000. Osaic Holdings Inc. boosted its stake in shares of BioNTech by 27.3% during the second quarter. Osaic Holdings Inc. now owns 1,949 shares of the company’s stock valued at $208,000 after purchasing an additional 418 shares during the period. Boothbay Fund Management LLC purchased a new stake in shares of BioNTech during the second quarter valued at approximately $319,000. Finally, Royal Bank of Canada boosted its stake in shares of BioNTech by 95.9% during the first quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after purchasing an additional 3,514 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.